Group 1 - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, including 16 comprehensive support policies [1][2] - The measures include accelerating innovative drug research and development, improving the payment system, and establishing a commercial health insurance catalog for innovative drugs [1][2] - Domestic pharmaceutical companies have made breakthroughs in internationalization, with Dize Pharmaceutical's Shuwotini receiving FDA approval, marking it as the first domestic innovative drug approved in the U.S. for EGFR exon 20 insertion non-small cell lung cancer [1] Group 2 - The innovative drug sector is experiencing a hot market, driven by policy support and overseas trading catalysts, with a notable increase in the chemical pharmaceutical sub-sector, which saw a weekly increase of 5.03% [2] - The introduction of a commercial health insurance catalog for innovative drugs is a significant development, focusing on clinically valuable innovative drugs and improving the adjustment mechanism for the medical insurance catalog [2] - The CXO and life sciences upstream industry chain demand is recovering due to active overseas authorization transactions for innovative drugs [2]

Core Viewpoint - Multiple favorable policies have been released, leading to a collective surge in innovative drug stocks, with Kangfang Biotech's market capitalization surpassing HKD 100 billion [9][11]. Market Performance - On July 4, the Hang Seng Index initially dropped over 1.5% but later narrowed its losses, closing down 0.64% at 23,916.06 points, with a weekly decline of 1.52% [2]. - The total market turnover was HKD 267.8 billion, with southbound funds net buying HKD 6.68 billion [4]. - The healthcare sector index rose by 0.8%, while the materials sector index fell by nearly 1.2% [7]. Stock Highlights - Kangfang Biotech's stock price increased by 9.43% to HKD 116.10, with a total market value reaching HKD 104.2 billion [9][12]. - Other innovative drug companies also saw significant gains, including: - Boan Biotech up 8.55% - Cloudtop New Drug up 4.84% - WuXi AppTec up 4.31% [11][12]. Policy Impact - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, which are expected to expand market opportunities and encourage R&D efforts [12][13]. - The introduction of a commercial insurance innovative drug directory is seen as a significant exploration of an innovative payment system, injecting new vitality into the innovative drug ecosystem [13].

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant gains in constituent stocks, indicating a positive trend in the healthcare sector [3]. Group 1: Market Performance - As of July 4, 2025, the HSHCI rose by 1.19%, with notable increases in stocks such as Huahao Zhongtian Pharmaceutical-B (02563) up 16.34% and Kangfang Biotech (09926) up 8.67% [3]. - The Hang Seng Healthcare ETF (513060) increased by 0.86%, with a latest price of 0.59 yuan, and has seen a cumulative increase of 3.57% over the past week [3]. - The ETF recorded a turnover rate of 18.66% during the trading session, with a transaction volume of 1.516 billion yuan, indicating active market participation [3]. Group 2: Investment Opportunities - Huatai Securities suggests that AI is expected to reshape drug development and healthcare service delivery, with increasing applications in the medical field, highlighting potential investment opportunities by 2025 [4]. - The Hang Seng Healthcare ETF has seen a significant growth in scale, with an increase of 191 million yuan over the past week, ranking in the top third among comparable funds [4]. - Leveraged funds are actively investing, with the latest financing buy-in amounting to 291 million yuan and a financing balance of 277 million yuan [4]. Group 3: Performance Metrics - The Hang Seng Healthcare ETF has achieved a net value increase of 18.78% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF has outperformed its benchmark with an annualized excess return of 1.73% over the past year, and a Sharpe ratio of 1.85 as of June 27, 2025 [4]. - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [4]. Group 4: Fee Structure and Valuation - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [5]. - The ETF's tracking error over the past year is 0.069%, the highest tracking precision among comparable funds [5]. - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 27.68, indicating a valuation below 90.41% of the historical data over the past three years, suggesting it is at a historical low [5]. Group 5: Index Composition - The top ten weighted stocks in the HSHCI account for 58.46% of the index, including companies like Innovent Biologics (01801) and BeiGene (06160) [5].